Directorate Change

Provexis PLC
24 July 2006



                                  PROVEXIS PLC

                         ('Provexis' or the 'Company')

                               Directorate Change


Provexis plc, the nutraceutical company that develops scientifically-proven
functional and medical foods, today announces that Dr Stephen Franklin is
stepping down with immediate effect from his role as Chief Executive Officer,
and will not be seeking re-election to the Board at the Company's forthcoming
Annual General Meeting. Dr Franklin will continue to work with the Company until
early 2007 as Acting Director of Research. In this capacity he will complement
the Company's research and development team progressing late phase development
of the Company's proprietary technologies. The Company announces that Stephen
Moon has been appointed as Chief Executive Officer with immediate effect.
Stephen Moon, formerly Commercial Director of Provexis, has been with the
Company since February 2003.

Stephen Moon has been central to the strategic development of the Company. He
has been responsible for identifying and implementing revenue generating
opportunities, in particular pursuing key licensing agreements, and was
instrumental in the successful launch of the Company's Sirco(TM)product, which
incorporates its patented Fruitflow(TM)technology, into the major UK
supermarkets, Tesco and Waitrose, in February 2006. Prior to joining Provexis,
Stephen worked as Strategy Planning and Worldwide Business Development Director
at GlaxoSmithKline's nutritional healthcare division and in manufacturing and
supply chain roles at BP, Dalgety and Quaker.

Dawson Buck, Chairman of Provexis plc said:

'The Board would like to thank Dr Stephen Franklin for his significant
contribution to the establishment and development of the Company, particularly
since the reverse takeover of Nutrinnovator in June 2005. In addition we are
pleased that he will continue to work with the Company in an advisory capacity.

'I am delighted that Stephen Moon has accepted the role of Chief Executive. He
is highly regarded in the global nutritional sector and his wealth of experience
and extensive knowledge of the Company will prove invaluable in the next stage
of Provexis' development.

'As stated at the preliminary results announcement, the Board is pleased with
the progress that the Company has made since its admission to AIM in June 2005.
We believe that the Company is well-positioned to continue its growth by
capitalising on global opportunities with potential licensing partners in the
rapidly growing functional and medical foods market.'

                                     

For further information please contact:

Dawson Buck, Chairman
Provexis plc                                                 Tel: [phone]

Emma Kent
Bell Pottinger Corporate & Financial                         Tel: [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange